Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-661 thorough QT study in healthy adults
NL-OMON42529Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tezacaftor in cystic fibrosis (CF) (6 arms), sponsored by Vertex Pharmaceuticals. Started Jul 2015; status: active, not recruiting.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON42529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42529.